Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:LCI NASDAQ:LRMR OTCMKTS:SEOVF NASDAQ:TLSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLCILannett$1.54$0.64▼$3.72$7.38M0.9592,067 shs280,600 shsLRMRLarimar Therapeutics$4.21+6.6%$4.12$1.61▼$9.50$348.50M14.60 million shs1.55 million shsSEOVFSernova Biotherapeutics$0.12+0.1%$0.13$0.10▼$0.19$38.93M1.089,880 shs31,844 shsTLSATiziana Life Sciences$1.94+2.1%$1.90$0.63▼$2.60$226.69M-0.37349,646 shs88,506 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLCILannett0.00%0.00%0.00%0.00%0.00%LRMRLarimar Therapeutics0.00%+0.24%-13.37%+8.51%-42.72%SEOVFSernova Biotherapeutics0.00%-4.80%-10.70%-16.25%-35.25%TLSATiziana Life Sciences0.00%-0.51%-6.28%+4.30%+100.35%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLCILannett$1.54$0.64▼$3.72$7.38M0.9592,067 shs280,600 shsLRMRLarimar Therapeutics$4.21+6.6%$4.12$1.61▼$9.50$348.50M14.60 million shs1.55 million shsSEOVFSernova Biotherapeutics$0.12+0.1%$0.13$0.10▼$0.19$38.93M1.089,880 shs31,844 shsTLSATiziana Life Sciences$1.94+2.1%$1.90$0.63▼$2.60$226.69M-0.37349,646 shs88,506 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLCILannett0.00%0.00%0.00%0.00%0.00%LRMRLarimar Therapeutics0.00%+0.24%-13.37%+8.51%-42.72%SEOVFSernova Biotherapeutics0.00%-4.80%-10.70%-16.25%-35.25%TLSATiziana Life Sciences0.00%-0.51%-6.28%+4.30%+100.35%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLCILannett 0.00N/AN/AN/ALRMRLarimar Therapeutics 2.80Moderate Buy$16.71297.01% UpsideSEOVFSernova Biotherapeutics 0.00N/AN/AN/ATLSATiziana Life Sciences 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest TLSA, LCI, LRMR, and SEOVF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025LRMRLarimar TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025TLSATiziana Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025LRMRLarimar TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TLSATiziana Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/2/2025LRMRLarimar TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$26.00 ➝ $21.009/30/2025LRMRLarimar TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$10.00 ➝ $7.009/30/2025LRMRLarimar TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$15.00 ➝ $11.009/27/2025LRMRLarimar TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TLSATiziana Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)8/15/2025LRMRLarimar TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$22.00 ➝ $18.00(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLCILannett$340.58M0.00N/AN/A($23.34) per share0.00LRMRLarimar TherapeuticsN/AN/AN/AN/A$2.69 per shareN/ASEOVFSernova BiotherapeuticsN/AN/AN/AN/A($0.03) per shareN/ATLSATiziana Life SciencesN/AN/AN/AN/A$0.04 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLCILannett-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/ALRMRLarimar Therapeutics-$80.60M-$1.56N/AN/AN/AN/A-62.92%-53.98%10/29/2025 (Estimated)SEOVFSernova Biotherapeutics-$23.65M-$0.04N/A∞N/AN/AN/A-475.30%10/27/2025 (Estimated)TLSATiziana Life Sciences-$11.86MN/A0.00∞N/AN/AN/AN/AN/ALatest TLSA, LCI, LRMR, and SEOVF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/29/2025Q3 2025LRMRLarimar Therapeutics-$0.40N/AN/AN/AN/AN/A9/15/2025Q3 2025SEOVFSernova Biotherapeutics-$0.0144-$0.01+$0.0044-$0.01N/AN/A8/14/2025Q2 2025LRMRLarimar Therapeutics-$0.47-$0.41+$0.06-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLCILannettN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/ASEOVFSernova BiotherapeuticsN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLCILannettN/A2.231.39LRMRLarimar TherapeuticsN/A5.465.46SEOVFSernova BiotherapeuticsN/A0.020.02TLSATiziana Life SciencesN/A1.72N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLCILannett40.28%LRMRLarimar Therapeutics91.92%SEOVFSernova BiotherapeuticsN/ATLSATiziana Life SciencesN/AInsider OwnershipCompanyInsider OwnershipLCILannett13.12%LRMRLarimar Therapeutics4.50%SEOVFSernova BiotherapeuticsN/ATLSATiziana Life Sciences39.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLCILannett81010.77 million9.35 millionOptionableLRMRLarimar Therapeutics3082.78 million79.05 millionOptionableSEOVFSernova BiotherapeuticsN/A328.48 millionN/ANot OptionableTLSATiziana Life Sciences8116.85 million70.32 millionOptionableTLSA, LCI, LRMR, and SEOVF HeadlinesRecent News About These CompaniesTiziana Life Sciences' (TLSA) "Sell (D-)" Rating Reaffirmed at Weiss RatingsOctober 25 at 12:42 AM | marketbeat.comTiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 3.5% - Should You Sell?October 18, 2025 | marketbeat.comWeiss Ratings Reiterates "Sell (D-)" Rating for Tiziana Life Sciences (NASDAQ:TLSA)October 9, 2025 | marketbeat.comTiziana Life Sciences to showcase drug candidate at Saudi innovation forumSeptember 30, 2025 | proactiveinvestors.comTiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi ArabiaSeptember 30, 2025 | globenewswire.comTiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 0.5% - Should You Sell?September 26, 2025 | marketbeat.comTiziana Life Sciences Stock Rises On Advancing Second Asset Besides Foralumab: Retail Thinks Stock Has ‘So Much Potential’September 25, 2025 | msn.comTiziana Life Sciences stock higher on inflammatory therapy plansSeptember 25, 2025 | proactiveinvestors.comTiziana to push ahead with second drug candidate in inflammation researchSeptember 25, 2025 | proactiveinvestors.comTiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal AntibodySeptember 25, 2025 | tmcnet.comTiziana Life Sciences Ltd (TLSA) Secures U.S. DoD Grant to Advance Intranasal Foralumab for Spinal Cord InjurySeptember 25, 2025 | finance.yahoo.comTiziana to share trial design for nasal MS drug at global congressSeptember 24, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS CongressSeptember 24, 2025 | globenewswire.comTiziana Life Sciences Ltd (TLSA) Secures U.S. DoD Grant to Advance Intranasal Foralumab for Spinal Cord InjurySeptember 23, 2025 | insidermonkey.comTiziana Life Sciences announces U.S. DoD awarded research grant to study SCISeptember 15, 2025 | msn.comTiziana Life Sciences Secures DoD Grant for Spinal Cord Injury ResearchSeptember 15, 2025 | msn.comTiziana Life Sciences awarded DoD grant to advance intranasal therapy for spinal cord injurySeptember 15, 2025 | proactiveinvestors.comDepartment of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord InjurySeptember 15, 2025 | globenewswire.comTiziana Life Sciences reports CEO purchased 14,848 sharesSeptember 10, 2025 | msn.comTiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerSeptember 9, 2025 | globenewswire.comTiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerSeptember 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTLSA, LCI, LRMR, and SEOVF Company DescriptionsLannett NYSE:LCILannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.Larimar Therapeutics NASDAQ:LRMR$4.21 +0.26 (+6.58%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$4.21 0.00 (0.00%) As of 10/24/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Sernova Biotherapeutics OTCMKTS:SEOVF$0.12 +0.00 (+0.08%) As of 10/24/2025 09:53 AM EasternSernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.Tiziana Life Sciences NASDAQ:TLSA$1.94 +0.04 (+2.11%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.88 -0.06 (-3.30%) As of 10/24/2025 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
